https://doi.org/10.4081/hmr.v2i5.751

Proteasome inhibitors: bortezomib in multiple myeloma

Vol. 2 No. 5: New Drugs in Hematology, Bologna, Italy 5-7 October 2008
Published: June 23, 2009
Abstract Views: 164
PDF: 201
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

M Cavo
support@pagepress.org
MC Pallotti
L Pantani
A Petrucci
A Brioli
C Terragna
N Testoni
G Marzocchi
S Durante
M Ceccolini
G Perrone
P Tacchetti
E Zamagni
P Tosi
M Baccarani
Over the past decade, new insights into the biology of multiple myeloma (MM) have provided the framework for the development of novel therapies to overcome drug resistance. In particular, recognition of the pivotal role of bone marrow microenvironment in promoting myeloma cell growth, survival, drug resistance, and migration has allowed for identification of specific therapeutic strategies targeting myeloma– stromal cell interactions and cytokine secretion in the bone marrow milieu. The first-in-class proteasome inhibitor bortezomib is an excellent example of this novel class of agents that has quickly translated from the bench to the bedside.

Dimensions

Altmetric

PlumX Metrics

Downloads

Citations

Crossref
Scopus
Google Scholar
Europe PMC

Supporting Agencies

How to Cite

Cavo, M., Pallotti, M., Pantani, L., Petrucci, A., Brioli, A., Terragna, C., Testoni, N., Marzocchi, G., Durante, S., Ceccolini, M., Perrone, G., Tacchetti, P., Zamagni, E., Tosi, P., & Baccarani, M. (2009). Proteasome inhibitors: bortezomib in multiple myeloma. Hematology Meeting Reports (formerly Haematologica Reports), 2(5). https://doi.org/10.4081/hmr.v2i5.751
Authors who publish with this journal agree to the following terms: Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).